close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

151.40 +0.28 (+0.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
71 72 Next >
News headline image
7 Dividend Stocks to Buy Now: June 2024 ↗
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
News headline image
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio? ↗
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%). 
Via Benzinga
News headline image
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
News headline image
Top Analyst Reports For Abbott, BP & Gilead ↗
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and... 
Via Talk Markets
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today ↗
 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Gilead Sciences ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today ↗
 
Via Benzinga
News headline image
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market ↗
Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concerns arise over lack of broad participation and high concentration in mega-cap... 
Via Benzinga
Topics Economy Stocks
News headline image
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
News headline image
Why Gilead Sciences Stock Is Trading Higher Friday ↗
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir. 
Via Benzinga
News headline image
Pre-Market Movers - June 21, 2024 ↗
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
News headline image
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. 
Via MarketBeat
News headline image
Defying the Norms: 3 High P/E Stocks With Room to Run ↗
Gilead Sciences, Crowdstrike and DataDog might be the best high P/E stocks to buy, offering substantial growth despite elevated valuations. 
Via InvestorPlace
News headline image
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday? ↗
After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declined after hitting all-time highs around midday trading in New York. This... 
Via Benzinga
Topics Stocks
News headline image
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective ↗
The company tested its HIV prevention drug in cisgender women in Uganda and South Africa. 
Via Investor's Business Daily
News headline image
Why Is Gilead Sciences Stock Trading Higher On Thursday? ↗
Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints,... 
Via Benzinga
News headline image
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender ↗
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
News headline image
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects ↗
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab. 
Via Benzinga
Topics Death
News headline image
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar ↗
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily
News headline image
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
From Gilead Sciences, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗
These stocks offer great dividends and more. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100? ↗
If you're looking for big income from blue-chip companies, these picks are for you. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today